Corbus Pharmaceuticals Holding Stock Today
| CRBP Stock | USD 37.16 3.96 9.63% |
Performance12 of 100
| Odds Of DistressOver 65
|
Corbus Pharmaceuticals is selling at 37.16 as of the 17th of April 2024; that is -9.63 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 36.09. Corbus Pharmaceuticals has more than 65 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Corbus Pharmaceuticals Holding are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of November 2014 | Category Healthcare | Classification Health Care |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Corbus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 10.51 M outstanding shares of which 475.63 K shares are currently shorted by private and institutional investors with about 1.24 trading days to cover. More on Corbus Pharmaceuticals Holding
Moving against Corbus Stock
| 0.81 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.75 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.73 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.63 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
| 0.61 | PLX | Protalix Biotherapeutics Financial Report 2nd of May 2024 | PairCorr |
| 0.54 | CYTHW | Cyclo Therapeutics | PairCorr |
| 0.42 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Corbus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Corbus Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Corbus Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO and Director | Yuval Cohen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cannabis (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Cannabis, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Corbus Pharmaceuticals report their recommendations after researching Corbus Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Corbus Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Corbus Pharmaceuticals. The Corbus consensus assessment is calculated by taking the average forecast from all of the analysts covering Corbus Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Corbus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Corbus Pharmaceuticals Holding may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Corbus Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corbus Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Corbus Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corbus Pharmaceuticals' financial leverage. It provides some insight into what part of Corbus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corbus Pharmaceuticals Holding (CRBP) is traded on NASDAQ Exchange in USA. It is located in 500 River Ridge Drive, Norwood, MA, United States, 02062 and employs 19 people. Corbus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 432.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corbus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Corbus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Corbus Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.51 M outstanding shares of which 475.63 K shares are currently shorted by private and institutional investors with about 1.24 trading days to cover.
Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Corbus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCorbus Pharmaceuticals retains a total of 10.51 Million outstanding shares. Over half of Corbus Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Corbus Pharmaceuticals. Please watch out for any change in the institutional holdings of Corbus Pharmaceuticals as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Corbus Ownership Details
Corbus Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Corbus Pharmaceuticals jumping above the current price in 90 days from now is about 26.14%. The Corbus Pharmaceuticals Holding probability density function shows the probability of Corbus Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.1337 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Corbus Pharmaceuticals will likely underperform. In addition to that, corbus Pharmaceuticals Holding has an alpha of 4.912, implying that it can generate a 4.91 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Corbus Pharmaceuticals to move above the current price in 90 days from now is about 26.14 (This Corbus Pharmaceuticals Holding probability density function shows the probability of Corbus Stock to fall within a particular range of prices over 90 days) .
Corbus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Corbus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corbus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corbus Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Group One Trading, Lp | 2023-12-31 | 1.8 K | |
| Tower Research Capital Llc | 2023-12-31 | 1.2 K | |
| Jtc Employer Solutions Trustee Ltd | 2023-12-31 | 1.1 K | |
| Citigroup Inc | 2023-12-31 | 566 | |
| Jpmorgan Chase & Co | 2023-12-31 | 543 | |
| Ubs Group Ag | 2023-12-31 | 321 | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 246 | |
| Carmichael Hill & Associates Inc | 2023-12-31 | 100.0 | |
| Bfsg, Llc | 2023-12-31 | 61.0 | |
| Ikarian Capital, Llc | 2023-12-31 | 195.9 K | |
| Vanguard Group Inc | 2023-12-31 | 179.5 K |
Corbus Pharmaceuticals Historical Income Statement
Corbus Pharmaceuticals Holding Income Statement is one of the three primary financial statements used for reporting Corbus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Corbus Pharmaceuticals revenue and expense. Corbus Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Corbus Pharmaceuticals' Non Operating Income Net Other is relatively stable compared to the past year. As of 04/17/2024, Interest Income is likely to grow to about 1.5 M, while EBITDA is likely to drop (46.7 M). View More FundamentalsCorbus Stock Against Markets
Picking the right benchmark for Corbus Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Corbus Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Corbus Pharmaceuticals is critical whether you are bullish or bearish towards Corbus Pharmaceuticals Holding at a given time. Please also check how Corbus Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Corbus Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Corbus Pharmaceuticals Corporate Directors
Corbus Pharmaceuticals corporate directors refer to members of a Corbus Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Corbus Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Corbus Pharmaceuticals' board members must vote for the resolution. The Corbus Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Ted Jenkins | Senior Director, Investor Relations and Communications | Profile | |
| John Jenkins | Director | Profile | |
| Alan Holmer | Independent Director | Profile | |
| Renu Gupta | Independent Director | Profile |
How to buy Corbus Stock?
Before investing in Corbus Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Corbus Pharmaceuticals. To buy Corbus Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Corbus Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Corbus Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Corbus Pharmaceuticals Holding stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Corbus Pharmaceuticals Holding stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Corbus Pharmaceuticals Holding, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Corbus Stock please use our How to Invest in Corbus Pharmaceuticals guide.
Already Invested in Corbus Pharmaceuticals Holding?
The danger of trading Corbus Pharmaceuticals Holding is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Corbus Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Corbus Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Corbus Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.